Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the Deferred Investment Award Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On October 12, 2009, the Administrators of the Deferred Investment Award Plan notified the Company of an increase in share interests for specific individuals following the re-investment of the dividend paid on October 9, 2009. The transaction price was £12.35 per share.
- Mr E J Gray: 266.45 shares
- Mr S A Hussain: 477.59 shares
- Mr D S Redfern: 210.79 shares
- Ms C Thomas: 131.74 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the routine disclosure of director share transactions.
Investor Verification Checklist
- Verify the dividend payment date of October 9, 2009, and the corresponding reinvestment price of £12.35.
- Confirm the total number of shares acquired by the named directors under the Deferred Investment Award Plan.
- Review the company's broader financial performance for the period ending October 2009 in separate earnings reports, as this filing contains no financial statements.